micTruely Your Radio Invalid ID

International

Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026

todayFebruary 4, 2026 1

share close

Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition

The maker of Wegovy and Ozempic, Novo Nordisk, has predicted a sharp drop in revenues this year owing to a push by Donald Trump to lower US weight-loss drug prices, rising competition and the loss of key patent protections.

Denmark’s Novo , once the poster-child for the growth in weight-loss treatments, said sales this year were likely to fall between 5% and 13%, despite the launch of its new Wegovy pill in the US. Its share price plummeted 18% on Wednesday morning, erasing all gains so far this year. In the past year the stock has lost nearly 50% of its value.

Continue reading…

Source: www.theguardian.com

Read full article

Written by: truelightfm

Rate it

Similar posts

Post comments (0)

Leave a reply

Your email address will not be published. Required fields are marked *